Influenza vaccine effectiveness in adults 65 years and older, Denmark, 2015/16 – a rapid epidemiological and virological assessment

H Emborg¹, TG Krause¹, L Nielsen², MK Thomsen³, CB Christiansen⁴, MN Skov⁵, XC Nielsen⁶, LS Weinreich⁷, TK Fischer⁸, J Rønn⁸, R Trebbien⁸

1. Department of Infectious Disease Epidemiology, Statens Serum Institut, Copenhagen, Denmark

2. Department of Clinical Microbiology, Herlev Hospital, Herlev, Denmark

3. Department of Clinical Microbiology, Aarhus University Hospital, Aarhus, Denmark

4. Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark

5. Department of Clinical Microbiology, Odense University Hospital, Odense C, Denmark

6. Department of Clinical Microbiology, Slagelse Hospital, Slagelse, Denmark

7. Department of Clinical Microbiology, Aalborg University Hospital, Aalborg, Denmark

8. Department of Microbiological Diagnostics and Virology, National Influenza Center, Statens Serum Institut, Copenhagen, Denmark

Correspondence: Hanne-Dorthe Emborg (hde@ssi.dk)

Citation style for this article:

Emborg H, Krause TG, Nielsen L, Thomsen MK, Christiansen CB, Skov MN, Nielsen XC, Weinreich LS, Fischer TK, Rønn J, Trebbien R. Influenza vaccine effectiveness in adults 65 years and older, Denmark, 2015/16 – a rapid epidemiological and virological assessment. *Euro Surveill.* 2016;21(14):pii=30189. DOI: <http://dx.doi.org/10.2807/1560-7917.ES.2016.21.14.30189>

Article submitted on 16 March 2016 / accepted on 07 April 2016 / published on 07 April 2016

In Denmark, both influenza A(H1N1)pdm09 and influenza B co-circulated in the 2015/16 season. We estimated the vaccine effectiveness (VE) of the trivalent influenza vaccine in patients 65 years and older using the test-negative case-control design. The adjusted VE against influenza A(H1N1)pdm09 was 35.0% (95% confidence interval (CI): 11.1–52.4) and against influenza B 4.1% (95% CI: –22.0 to 24.7). The majority of influenza A(H1N1)pdm09 circulating in 2015/16 belonged to the new genetic subgroup subclade 6B.1.

In Denmark, both influenza A(H1N1)pdm09 and influenza B co-circulated in the 2015/16 season. The trivalent influenza vaccine (TIV) did not include the circulating influenza B Victoria lineage and there is evidence in Europe for genetic evolution of the circulating influenza A(H1N1)pdm09 virus [1]. We estimated the influenza vaccine effectiveness (VE) in people aged 65 years and older. In addition, we describe the genetic and antigenic characteristics of the influenza A(H1N1)pdm09 variant and the influenza B strain circulating in Denmark.

Data for vaccine effectiveness estimation

In the Danish Microbiology Database, all patients swabbed at the general practitioner's (GP) or at hospital and tested for influenza A and B viruses by PCR are registered in real time [2]. During the influenza season, national guidelines recommend that patients belonging to risk groups, including the elderly who present with influenza symptoms at GPs and hospitals are swabbed and tested for influenza. At hospitals, all patients with

lower respiratory infections are also recommended to be swabbed. All diagnostic influenza tests from patients aged 65 years and older were included in this study.

Influenza symptoms were defined as sudden onset of fever, muscle ache and upper airway symptoms. The trivalent influenza vaccine (TIV) is offered free of charge to Danish citizens 65 and older between week 40 and week 53, and date of vaccination is registered in the Danish Vaccination Register [3]. In The Danish National Hospital Register, data on all hospital admissions are collected [4]. Comorbidities that can lead to severe influenza disease and were diagnosed between October 2010 and October 2015 were extracted from the Danish National Hospital Register.

Data from the Danish Microbiology Database, the Danish Vaccination Register and the Danish National Hospital Register were linked using unique identifiers.

Case definitions and statistical analysis

Cases were defined as patients who tested positive for influenza A(H1N1)pdm09 or influenza B, and a patient was only included the first time a test was positive for either type. Controls were patients who tested negative for both influenza A and B. Patients were considered vaccinated if they had received the TIV at least two weeks before the sample was taken. A logistic regression model was used to estimate VE against influenza A(H1N1)pdm09 and influenza B using the test-negative case-control design $(1-OR) \times 100\%$. The

FIGURE 1

Trivalent influenza vaccines received (n = 1,831) and laboratory-confirmed influenza A(H1N1)pdm09 and B cases among tested patients ≥ 65 years (n = 468), Denmark, 28 September 2015–9 March 2016

Influenza vaccines are given free of charge to the elderly 65 years and older from 1 October to 31 December. Due to delay in registration of vaccinations, data from week 53 were not available at the time this analysis was performed.

In weeks 40 to 53, between 0 and two influenza A(H1N1) and B cases were registered per week (not visible at presented range of the y-axis).

estimates were adjusted for sex and co-morbidities diagnosed within a five-year period before the 2015/16 influenza season. Among 195 subtyped influenza A isolates from patients aged 65 years and older, less than 10% (n = 18) were A(H3N2) and VE against this subtype was not estimated.

The statistical programme SAS version 9.4 was used for the descriptive and statistical analyses (SAS Institute, Cary, United States).

Influenza virus characterisation

All influenza samples received at The National Influenza Center in Denmark (NIC) were screened for influenza virus by an in-house multiplex real-time reverse-transcriptase PCR (qRT-PCR), with primers and probes detecting influenza A and B virus as well as subtypes of H3 haemagglutinin (HA) and N1pdm09 neuraminidase. Subtyping of influenza B virus is also performed by an in-house duplex qRT-PCR which differentiates between the Yamagata and Victoria lineage on a fragment of the HA gene.

Sequencing of the HA gene of influenza A(H1N1)pdm09 and influenza B viruses was performed on extracted viral RNA from 62 and 20 samples, respectively. Total nucleic acid was extracted using 200 µl of sample material and the MagNA Pure LC Total Nucleic Acid Isolation Kit on the MagNa Pure 96/32 (Roche). RT-PCR

of the complete HA gene was performed using in-house primers and an in-house one-step RT-PCR programme on a TRIO cyclor (Biometra). Sequencing was performed by using Big Dye chemistry on an ABI3500 capillary sequencer (Thermo Fisher). Assembly of contigs was done in Bionumerics version 6.6 (Applied maths) and alignment and phylogenetic analysis were conducted with MEGA version 6 [5]. For alignment, the Muscle algorithm was used and phylogenetic trees were created by the maximum likelihood method using 1,000 bootstrap replicates. Sequences were also analysed by BLAST at NCBI GenBank, the Global Initiative on Sharing All Influenza Data (GISAID) and at the FLUSERVER [6]. The authors gratefully acknowledge the 59 originating and submitting laboratories who contributed sequences used in the phylogenetic analysis to GISAID (www.gisaid.org).

Virus isolation was successful for 32 influenza A(H1N1)pdm09 and 13 influenza B samples by standard procedures in confluent monolayers of MDCK and/or MDCK-SIAT cells [7]. Several samples were shipped in E-swab medium which is cytotoxic and therefore is challenging for virus isolation [8]. Antigenic characterisation was performed by HA inhibition (HAI) test [7] using reference ferret antiserum against A/California/07/2009 (H1N1pdm09), B/Brisbane/60/2008 (Victoria lineage) and B/Phuket/3073/2013 (Yamagata lineage) provided

FIGURE 2

Phylogenetic tree of the haemagglutinin gene with reference viruses for the different phylogenetic clades of H1N1pdm09 influenza A viruses (n = 40)

The Danish viruses are indicated with a black circle, A subclade formed by viruses with the amino acid substitutions S101N, S179N and I233T, subclade 6B.1, is indicated as well as the subclade formed by viruses with the V169T, V190I, E508G and D518E substitutions, subclade 6B.2. The authors gratefully acknowledge the 59 originating and submitting laboratories who contributed sequences used in the phylogenetic analysis to GISAID (www.gisaid.org).

TABLE

Laboratory-confirmed influenza A(H1N1)pdm09 and B cases (n = 468) and influenza A and B test-negative controls (n = 3,363) aged ≥ 65 years by trivalent influenza vaccination status, age group and sex, and vaccination coverage among influenza cases and controls by age group and sex, Denmark, 28 September 2015–9 March 2016

Characteristic	Influenza A(H1N1)pdm09			Influenza B			Controls		
	Vaccinated (n)	Not vaccinated (n)	Vaccination coverage (%)	Vaccinated (n)	Not vaccinated (n)	Vaccination coverage (%)	Vaccinated (n)	Not vaccinated (n)	Vaccination coverage (%)
Age group									
65–69	16	42	27.6	37	42	46.8	337	488	40.8
70–74	20	29	40.8	37	41	47.4	385	458	45.7
75–79	18	22	45.0	27	34	44.3	363	323	52.9
≥ 80	13	17	43.3	34	39	46.6	544	466	53.9
Comorbidities									
No	15	34	30.6	36	66	35.3	347	480	42.0
Yes	52	76	40.6	99	90	52.4	1,282	1,255	50.5
Sex									
Female	28	45	38.4	70	79	50.0	780	865	47.4
Male	39	65	37.5	65	77	45.8	849	869	49.4
Total	67	110	37.8	135	156	46.4	1,629	1,734 ^a	48.3

^a Sex was not known for one person.

by the World Health Organization (WHO) Collaboration Centre, Mill Hill, London.

Vaccine effectiveness results

By 9 March 2016, 3,831 patients 65 years and older were tested for influenza A(H1N1)pdm09 and B, and 65% of them were swabbed at a hospital. In total, 177 patients were positive for influenza A(H1N1)pdm09 and 291 for influenza B. In total, 1,505 (82%) of 1,831 study participants had received the TIV before 2 November in 2015 (Figure 1).

Vaccine coverage in cases diagnosed with influenza A(H1N1)pdm09 was 37.8%, which is lower than the coverage in controls (48.3%), cases diagnosed with influenza B (46.4%) (Table) and the estimated national coverage of 44% (data not shown). The coverage, for both cases and controls, was higher among patients with comorbidities compared with patients without comorbidities (Table).

Adjusted interim VE among those aged 65 years and older against influenza A(H1N1)pdm09 was 35.0% (95% confidence interval (CI): 11.1–52.4) and against influenza B 4.1% (95% CI: –22.0 to 24.7).

Virus characterisation results

Full gene sequencing of the HA gene from 62 influenza A(H1N1)pdm09 samples revealed in 46 of them an amino acid substitution at position 179 (H1 complete open reading frame numbering) from serine to asparagine, which leads to a potential glycosylation site formed by positions 179–181 with the amino acid motif asparagine–glutamine–serine (NQS) (Table).

Additional substitutions were revealed at amino acid position S101N and I233T in the 46 samples having the S179N. Two of the patient samples had an additional substitution at H155Y. Nine samples had a different amino acid motif with substitutions at positions V169T, V190I, E508G and D518E.

Phylogenetic analysis revealed that all 62 sequenced HA genes of A(H1N1)pdm09 viruses belonged to genetic clade 6B (Figure 2), however, the 46 viruses with the S101N, S179N, and I233T substitutions formed their own subclade which now is categorised by the WHO as subclade 6B.1. In addition, the nine V169T, V190I, E508G and D518E viruses clustered together with the A/Minnesota/32/2015(H1N1)pdm09 virus (Figure 2) and are now categorised as subclade 6B.2.

Of the 32 A(H1N1)pdm09 viruses isolated in cell culture, 25 belonged to subclade 6B.1, three belonged to subclade 6B.2, and four belonged to clade 6B. Antigenic characterisation showed all 32 virus isolates to be equally inhibited or inhibited to a lesser extent (two- to fourfold decrease in HAI titre), by ferret antiserum against A/California/07/2009 (H1N1)pdm09 compared with the A/California/07/2009 (H1N1)pdm09 reference virus HAI titres.

Of 447 influenza B virus samples from all age groups received for the national influenza surveillance programme at NIC Denmark by mid-March 2016, 350 were subtyped; 307 (88%) belonged to the B-Victoria lineage and 43 (12%) belonged to the B-Yamagata lineage. The HA genes of 15 B-Victoria viruses were sequenced and all belonged to clade 1A, corresponding to the

strain included in the quadrivalent vaccine but not included in the trivalent vaccine used in Denmark in the current season. Antigenic characterisation by HAI test of 13 virus isolates showed a two- to fourfold decrease in HAI-titre using the ferret antiserum against B/Brisbane/60/2008 compared with the vaccine reference virus B/Brisbane/60/2008. None of the B-Victoria viruses was inhibited by the B-Yamagata reference antiserum B/Phuket/3073/2013.

Discussion

Due to the late start of the influenza season in Europe only few interim VE estimates have been published [9,10] and in particular, little information is available on the VE in those aged 65 years and older, an important target group for influenza vaccination. Furthermore, a mismatch was observed between the circulating B-Victoria lineage and the B-Yamagata lineage included in the TIV for the northern hemisphere.

We found no effect of the TIV against influenza B 4.1% (95% CI: -22.0 to 24.7), which accounted for 62% of the influenza detections in patients aged 65 years and older in Denmark until 9 March 2016. This can be explained by the mismatch because 88% of the B infections were Victoria lineage. This is in line with findings from Hong Kong in 2011/12 where B-Victoria was included in the vaccine and VE against paediatric influenza B-Yamagata hospitalisation was estimated at 9.5% (95% CI: -240.4 to 76.0) [11]. However, in the same season, a study from the United States estimated a VE of 66% (95% CI: 38–81) against B-Yamagata although only the B-Victoria lineage was included in the vaccine [12], which could suggest cross-protection between lineages. Antigenic characterisation at the Danish NIC supports a lack of cross-reactivity between B-Yamagata and B-Victoria when using the current season's vaccine antiserum against B/Brisbane/60/2008 and B/Phuket/3073/2013 in the HAI test which is also reported in the study from Hong Kong [11]. Influenza B lineage-specific TIV VEs have earlier been estimated in seasons with both mismatch and/or cocirculation of two influenza B lineages. Some VE studies have suggested cross-protection between lineages and others not. The reasons for these differences are not known but may be explained by methodological issues or by differences in population immunity due to variations in vaccination strategies or differences in circulating lineages between regions [13].

It is likely that immunity against influenza B Victoria in the Danish population is low, as only few isolates from this lineage have been detected in Denmark since 2010/11 and have not been included in the vaccine since 2011/12. Influenza B-Victoria also dominates over B-Yamagata in the rest of Europe [14], and if the quadrivalent vaccine had been used instead of TIV during the current season morbidity due to influenza B might have been lower.

We found a moderate to low VE against influenza A(H1N1)pdm09 of 35.0% (95% CI: 11.1–52.4) in patients aged 65 years and older, although the majority of influenza A(H1N1)pdm09 circulating in Denmark in the 2015/16 season belonged to the new genetic subclade 6B.1. VE against influenza A(H1N1)pdm09 in the current season was similar to the VE against influenza A(H1N1)pdm09 in the 2014/15 season in Denmark of 31% (95% CI: -0.7 to 52.7) where 114 patients were positive for influenza A(H1N1)pdm09 and 3,351 patients tested negative (data not shown). This estimate also corresponds to the estimated VE of 22% (95% CI: -44.4 to 58.4) against influenza A(H1N1)pdm09 in the same age group in season 2014/15 reported by I-Move following a multicentre case-control study [15].

Conclusion

We estimated similar VE against influenza A(H1N1)pdm09 in season 2014/15 and 2015/16 in those aged 65 years and older in spite of the occurrence of the new subclade 6B.1. This is reassuring as the WHO recommendations for the influenza A(H1N1)pdm09 component in the 2016/17 vaccine for the northern hemisphere remained the same as in previous years, while the influenza B component changed from Yamagata to Victoria [16].

Acknowledgement

Test results for influenza virus were obtained from the Danish Microbiology Database (MiBa, <http://miba.ssi.dk>), which contains all electronic reports from departments of clinical microbiology in Denmark since 2010, and we acknowledge the collaboration with the MiBa Board of Representatives.

The authors gratefully acknowledge the 59 originating and submitting laboratories who contributed sequences used in the phylogenetic analysis to GISAID (www.gisaid.org).

We also acknowledge for the laboratory work, Dennis Jelsbak Schmidt and Bente Andersen, National Influenza Center Denmark, Statens Serum Institut, Copenhagen, Denmark.

Statens Serum Institut would also like to acknowledge the participation in the I-MOVE+ (Integrated Monitoring of Vaccines in Europe) project that has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 634446.

Conflict of interest

None declared.

Authors' contributions

Hanne-Dorthe Emborg led the writing of the paper. Ramona Trebbien was responsible for the virological characterisation and Jesper Rønn for the laboratory work. Lene Nielsen, Marianne Kragh Thomsen, Claus Bohn Christiansen, Marianne Nielsine Skov, Xiaohui Chen Nielsen and Lenette Sandborg Weinreich performed the initial diagnostics of influenza positive samples. Tyra Grove Krause and Thea Kølsten Fischer conceptualised the study together with Hanne-Dorthe Emborg and Ramona Trebbien and discussed

the data and perspectives. All authors provided contributions to the paper and approved the final version.

credit to the source, provide a link to the licence, and indicate if changes were made.

This article is copyright of the authors, 2016.

References

1. European Centre for Disease Prevention and Control (ECDC). Seasonal influenza 2015-2016 in the EU/EEA countries. Risk assessment. Stockholm: ECDC; 2016. Available from: <http://ecdc.europa.eu/en/publications/Publications/seasonal-influenza-risk-assessment-2015-2016.pdf>
2. MiBa Board of Representatives, Voldstedlund M, Haarh M, Mølbak K. The Danish Microbiology Database (MiBa) 2010 to 2013. *Euro Surveill.* 2014;19(1):20667. DOI: 10.2807/1560-7917.ES2014.19.1.20667 PMID: 24434175
3. Grove Krause T, Jakobsen S, Haarh M, Mølbak K. The Danish vaccination register. *Euro Surveill.* 2012;17(17):2015. PMID: 22551494
4. Andersen TF, Madsen M, Jørgensen J, Mellemkjær L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. *Dan Med Bull.* 1999;46(3):263-8. PMID: 10421985
5. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. *Mol Biol Evol.* 2013;30(12):2725-9. DOI: 10.1093/molbev/mst197 PMID: 24132122
6. FluSurver. Influenza surveillance - prepared for next wave. Singapore; A*STAR Bioinformatics Institute. [Accessed: 14 Mar 2016]. Available from: <http://flusurver.bii.a-star.edu.sg/>
7. World Health Organization (WHO) Global Influenza Surveillance Network. Manual for the laboratory diagnosis and virological surveillance of influenza. Geneva: WHO; 2011. Available from: http://apps.who.int/iris/bitstream/10665/44518/1/9789241548090_eng.pdf
8. Trebbien R, Andersen B, Rønn J, McCauley J, Fischer TK. ESwab challenges influenza virus propagation in cell cultures. *Euro Surveill.* 2014;19(50):20995. DOI: 10.2807/1560-7917.ES2014.19.50.20995 PMID: 25597539
9. Kissling E, Valenciano M. Early influenza vaccine effectiveness results 2015-16: I-MOVE multicentre case-control study. *Euro Surveill.* 2016;21(6):30134. DOI: 10.2807/1560-7917.ES.2016.21.6.30134 PMID: 26898240
10. Pebody R, Warburton F, Ellis J, Andrews N, Potts A, Cottrell S, et al. Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 mid-season results. *Euro Surveill.* 2016;21(13):30179.
11. Chiu SS, Feng S, Chan KH, Lo JY, Chan EL, So LY, et al. Hospital-based vaccine effectiveness against influenza B lineages, Hong Kong, 2009-14. *Vaccine.* 2016;pii: S0264-410X(16)30005-6
12. Ohmit SE, Thompson MG, Petrie JG, Thaker SN, Jackson ML, Belongia EA, et al. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. *Clin Infect Dis.* 2014;58(3):319-27. DOI: 10.1093/cid/cit736 PMID: 24235265
13. Skowronski DM, Janjua NZ, Sabaiduc S, De Serres G, Winter AL, Gubbay JB, et al. Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. *J Infect Dis.* 2014;210(1):126-37. DOI: 10.1093/infdis/jiu048 PMID: 24446529
14. European Centre for Disease Prevention and Control (ECDC). Influenza situation in week 9 2016. Stockholm: ECDC; 2016. Available from: http://ecdc.europa.eu/en/healthtopics/seasonal_influenza/epidemiological_data/Pages/Latest_surveillance_data.aspx
15. Valenciano M, Kissling E, Reuss A, Rizzo C, Gherasim A, Horváth JK, et al. Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15. *Euro Surveill.* 2016;21(7):30139. DOI: 10.2807/1560-7917.ES.2016.21.7.30139 PMID: 26924024
16. Eurosurveillance editorial team., WHO recommendations on the composition of the 2016/17 influenza virus vaccines in the northern hemisphere. *Euro Surveill.* 2016;21(8):30147.

License and copyright

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate